The US Drug Agency approves a generic version of a preventive treatment for HIV

The FDA has approved a generic version of lenacapavir, a semi-annual injection for HIV prevention, making it accessible in 120 low- and middle-income countries. The expected cost is $40 per year per person, similar to daily preventive pills, but with greater convenience. Advocates believe this will significantly reduce HIV cases and deaths, as 41 million people live with HIV globally. The generic was developed by Dr. Reddy's Laboratories and aims to expand access to those in need. While the generic cannot be sold in the U.S. due to patent protections, it is expected to be available soon in other countries, pending local approvals. Funding and distribution remain challenges for widespread access.